A carregar...
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults
INTRODUCTION: Respiratory syncytial virus (RSV) infection causes respiratory disease throughout life, with infants and the elderly at risk of severe disease and death. RSV001 is a phase 1 (first-in-man), open-label, dose-escalation, clinical trial of novel genetic viral-vectored vaccine candidates P...
Na minha lista:
Publicado no: | BMJ Open |
---|---|
Main Authors: | , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BMJ Publishing Group
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4636663/ https://ncbi.nlm.nih.gov/pubmed/26510727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2015-008748 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|